林业发展局警告说,出于安全考虑,不得使用Fullerton Wellness的复合药物。 The FDA warns against using compounded drugs from Fullerton Wellness due to safety concerns.
林业发展局在发现使用非消毒成分和绝育过程不当之后,从加利福尼亚的Fullerton Wellness有限责任公司发出了关于复合药物的安全警报。 The FDA has issued a safety alert regarding compounded drugs from Fullerton Wellness, LLC, in California, after discovering the use of non-sterile ingredients and inadequate sterilization processes. 建议患者停止使用这些药物,包括西马格卢提德和提泽帕提德,并咨询医疗保健提供者. Patients are advised to stop using these drugs, which include semaglutide and tirzepatide, and consult their healthcare providers. 保健专业人员应隔离这些产品,避免对其进行管理。 Healthcare professionals should quarantine these products and refrain from administering them. 没有报告任何不良反应,但任何反应应报告给FDA. There have been no reported adverse events, but any reactions should be reported to the FDA.